Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2011, Article ID 267257, 9 pages
http://dx.doi.org/10.4061/2011/267257
Review Article

Peripheral Vascular Dysfunction in Chronic Kidney Disease

Department of Kinesiology & Applied Physiology, University of Delaware, 541 South College Avenue, Newark, DE 19716, USA

Received 24 December 2010; Accepted 15 March 2011

Academic Editor: Abarmard Maziar Zafari

Copyright © 2011 Christopher R. Martens and David G. Edwards. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Coresh, B. C. Astor, T. Greene, G. Eknoyan, and A. S. Levey, “Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey,” American Journal of Kidney Diseases, vol. 41, no. 1, pp. 1–12, 2003. View at Google Scholar · View at Scopus
  2. P. Muntner, J. He, L. Hamm, C. Loria, and P. K. Whelton, “Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States,” Journal of the American Society of Nephrology, vol. 13, no. 3, pp. 745–753, 2002. View at Google Scholar · View at Scopus
  3. M. J. Sarnak, A. S. Levey, A. C. Schoolwerth et al., “Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention,” Circulation, vol. 108, no. 17, pp. 2154–2169, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Vanholder, R. De Smet, G. Glorieux et al., “Review on uremic toxins: classification, concentration, and interindividual variability,” Kidney International, vol. 63, no. 5, pp. 1934–1943, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. S. Go, G. M. Chertow, D. Fan, C. E. McCulloch, and C. Y. Hsu, “Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization,” The New England Journal of Medicine, vol. 351, no. 13, pp. 1296–1370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. N. M. Isbel, B. Haluska, D. W. Johnson, E. Beller, C. Hawley, and T. H. Marwick, “Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function,” American Heart Journal, vol. 151, no. 3, pp. 745–753, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Davignon and P. Ganz, “Role of endothelial dysfunction in atherosclerosis,” Circulation, vol. 109, no. 23, pp. 27–32, 2004. View at Google Scholar · View at Scopus
  8. S. Sitia, L. Tomasoni, F. Atzeni et al., “From endothelial dysfunction to atherosclerosis,” Autoimmunity Reviews, vol. 9, no. 12, pp. 830–834, 2010. View at Publisher · View at Google Scholar
  9. D. Fischer, S. Rossa, U. Landmesser et al., “Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death,” European Heart Journal, vol. 26, no. 1, pp. 65–69, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Heitzer, S. Baldus, Y. von Kodolitsch, V. Rudolph, and T. Meinertz, “Systemic endothelial dysfunction as an early predictor of adverse outcome in heart failure,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 6, pp. 1174–1179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. S. D. Katz, K. Hryniewicz, I. Hriljac et al., “Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure,” Circulation, vol. 111, no. 3, pp. 310–314, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Félétou and P. M. Vanhoutte, “Endothelial dysfunction: a multifaceted disorder,” American Journal of Physiology, vol. 291, no. 3, pp. H985–H1002, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Perticone, R. Maio, M. Perticone et al., “Endothelial dysfunction and subsequent decline in glomerular filtration rate in hypertensive patients,” Circulation, vol. 122, no. 4, pp. 379–384, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. G. M. London, B. Pannier, M. Agharazii, A. P. Guerin, F. H. M. Verbeke, and S. J. Marchais, “Forearm reactive hyperemia and mortality in end-stage renal disease,” Kidney International, vol. 65, no. 2, pp. 700–704, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. A. S. Levey, J. Coresh, K. Bolton et al., “K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification,” American Journal of Kidney Diseases, vol. 39, supplement 1, no. 2, pp. S1–S266, 2002. View at Google Scholar
  16. M. Ketteler and P. H. Biggar, “Review article: getting the balance right: assessing causes and extent of vascular calcification in chronic kidney disease,” Nephrology, vol. 14, no. 4, pp. 389–394, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. L. J. Ignarro, G. M. Buga, K. S. Wood, R. E. Byrns, and G. Chaudhuri, “Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 24, pp. 9265–9269, 1987. View at Google Scholar · View at Scopus
  18. R. M. J. Palmer, D. S. Ashton, and S. Moncada, “Vascular endothelial cells synthesize nitric oxide from L-arginine,” Nature, vol. 333, no. 6174, pp. 664–666, 1988. View at Google Scholar · View at Scopus
  19. P. J. Andrew and B. Mayer, “Enzymatic function of nitric oxide synthases,” Cardiovascular Research, vol. 43, no. 3, pp. 521–531, 1999. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Moncada and A. Higgs, “The L-arginine-nitric oxide pathway,” The New England Journal of Medicine, vol. 329, no. 27, pp. 2002–2012, 1993. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Kubes, M. Suzuki, and D. N. Granger, “Nitric oxide: an endogenous modulator of leukocyte adhesion,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 11, pp. 4651–4655, 1991. View at Google Scholar · View at Scopus
  22. T. Scott-Burden and P. M. Vanhoutte, “The endothelium as a regulator of vascular smooth muscle proliferation,” Circulation, vol. 87, no. 5, pp. V51–V55, 1993. View at Google Scholar · View at Scopus
  23. S. Taddei, L. Ghiadoni, A. Virdis, D. Versari, and A. Salvetti, “Mechanisms of endothelial dysfunction: clinical significance and preventive non-pharmacological therapeutic strategies,” Current Pharmaceutical Design, vol. 9, no. 29, pp. 2385–2402, 2003. View at Publisher · View at Google Scholar
  24. D. S. Celermajer, K. E. Sorensen, V. M. Gooch et al., “Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis,” The Lancet, vol. 340, no. 8828, pp. 1111–1115, 1992. View at Publisher · View at Google Scholar
  25. M. I. Yilmaz, J. Axelsson, A. Sonmez et al., “Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 3, pp. 535–541, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. I. Yilmaz, M. Saglam, A. Sonmez et al., “Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: Ramipril versus valsartan,” Blood Purification, vol. 25, no. 4, pp. 327–335, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. P. W. B. Nanayakkara, C. van Guldener, P. M. ter Wee et al., “Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the anti-oxidant therapy in chronic renal insufficiency (ATIC) study,” Archives of Internal Medicine, vol. 167, no. 12, pp. 1262–1270, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Annuk, L. Lind, T. Linde, and B. Fellström, “Impaired endothelium-dependent vasodilatation in renal failure in humans,” Nephrology Dialysis Transplantation, vol. 16, no. 2, pp. 302–306, 2001. View at Google Scholar · View at Scopus
  29. M. Annuk, M. Zilmer, L. Lind, T. Linde, and B. Fellström, “Oxidative stress and endothelial function in chronic renal failure,” Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2747–2752, 2001. View at Google Scholar · View at Scopus
  30. M. Annuk, B. Fellström, and L. Lind, “Cyclooxygenase inhibition improves endothelium-dependent vasodilation in patients with chronic renal failure,” Nephrology Dialysis Transplantation, vol. 17, no. 12, pp. 2159–2163, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Annuk, I. Soveri, M. Zilmer, L. Lind, J. Hulthe, and B. Fellström, “Endothelial function, CRP and oxidative stress in chronic kidney disease,” Journal of Nephrology, vol. 18, no. 6, pp. 721–726, 2005. View at Google Scholar · View at Scopus
  32. L. Ghiadoni, A. Cupisti, Y. Huang et al., “Endothelial dysfunction and oxidative stress in chronic renal failure,” Journal of Nephrology, vol. 17, no. 4, pp. 512–519, 2004. View at Google Scholar · View at Scopus
  33. V. Costa-Hong, L. A. Bortolotto, V. Jorgetti, F. Consolim-Colombo, E. M. Krieger, and J. J. Galvao de Lima, “Oxidative stress and endothelial dysfunction in chronic kidney disease,” Arquivos Brasileiros de Cardiologia, vol. 92, no. 5, pp. 413–418, 2009. View at Google Scholar · View at Scopus
  34. J. M. Cross, A. E. Donald, S. L. Nuttall, J. E. Deanfield, R. G. Woolfson, and R. J. MacAllister, “Vitamin C improves resistance but not conduit artery endothelial function in patients with chronic renal failure,” Kidney International, vol. 63, no. 4, pp. 1433–1442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. J. M. Cross, A. E. Donald, R. Kharbanda, J. E. Deanfield, R. G. Woolfson, and R. J. MacAllister, “Acute administration of L-arginine does not improve arterial endothelial function in chronic renal failure,” Kidney International, vol. 60, no. 6, pp. 2318–2323, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. R. J. Schmidt, S. Yokota, T. S. Tracy, M. I. Sorkin, and C. Baylis, “Nitric oxide production is low in end-stage renal disease patients on peritoneal dialysis,” American Journal of Physiology, vol. 276, no. 5, pp. F794–F797, 1999. View at Google Scholar
  37. S. T. W. Morris, J. J. V. McMurray, A. Spiers, and A. G. Jardine, “Impaired endothelial function in isolated human uremic resistance arteries,” Kidney International, vol. 60, no. 3, pp. 1077–1082, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. J. A. Kari, A. E. Donald, D. T. Vallance et al., “Physiology and biochemistry of endothelial function in children with chronic renal failure,” Kidney International, vol. 52, no. 2, pp. 468–472, 1997. View at Google Scholar · View at Scopus
  39. G. Hussein, Y. Bughdady, M. E. Kandil, H. M. Bazaraa, and H. Taher, “Doppler assessment of brachial artery flow as a measure of endothelial dysfunction in pediatric chronic renal failure,” Pediatric Nephrology, vol. 23, no. 11, pp. 2025–2030, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. A. C. Wilson, E. Urbina, S. A. Witt, B. J. Glascock, T. R. Kimball, and M. Mitsnefes, “Flow-mediated vasodilatation of the brachial artery in children with chronic kidney disease,” Pediatric Nephrology, vol. 23, no. 8, pp. 1297–1302, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. C. Baylis, “Nitric oxide deficiency in chronic kidney disease,” American Journal of Physiology, vol. 294, no. 1, pp. F1–F9, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Higashi, K. Noma, M. Yoshizumi, and Y. Kihara, “Endothelial function and oxidative stress in cardiovascular diseases,” Circulation Journal, vol. 73, no. 3, pp. 411–418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. T. J. Guzik and D. G. Harrison, “Vascular NADPH oxidases as drug targets for novel antioxidant strategies,” Drug Discovery Today, vol. 11, no. 11-12, pp. 524–533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. B. P. Oberg, E. McMenamin, F. L. Lucas et al., “Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease,” Kidney International, vol. 65, no. 3, pp. 1009–1016, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. M. I. Yilmaz, M. Saglam, K. Caglar et al., “The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine,” American Journal of Kidney Diseases, vol. 47, no. 1, pp. 42–50, 2006. View at Publisher · View at Google Scholar
  46. C. K. Chen, J. M. Liaw, J. G. Juang, and T. E. H. Lin, “Antioxidant enzymes and trace elements in hemodialyzed patients,” Biological Trace Element Research, vol. 58, no. 1-2, pp. 149–157, 1997. View at Google Scholar · View at Scopus
  47. N. Takahashi, S. Morimoto, M. Okigaki et al., “Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients,” Nephrology, Dialysis, Transplantation, vol. 26, no. 4, pp. 1252–1257, 2011. View at Publisher · View at Google Scholar
  48. E. Linden, W. Cai, J. C. He et al., “Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation,” Clinical Journal of the American Society of Nephrology, vol. 3, no. 3, pp. 691–698, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Vasdev, V. Gill, and P. Singal, “Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications,” Cell Biochemistry and Biophysics, vol. 49, no. 1, pp. 48–63, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. G. Hasdan, S. Benchetrit, G. Rashid, J. Green, J. Bernheim, and M. Rathaus, “Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide,” Kidney International, vol. 61, no. 2, pp. 586–590, 2002. View at Publisher · View at Google Scholar · View at Scopus
  51. M. Tepel, M. van der Giet, M. Statz, J. Jankowski, and W. Zidek, “The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial,” Circulation, vol. 107, no. 7, pp. 992–995, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Boaz, S. Smetana, T. Weinstein et al., “Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial,” The Lancet, vol. 356, no. 9237, pp. 1213–1218, 2000. View at Google Scholar · View at Scopus
  53. N. F. Wiernsperger, “Oxidative stress as a therapeutic target in diabetes: revisiting the controversy,” Diabetes and Metabolism, vol. 29, no. 6, pp. 579–585, 2003. View at Google Scholar · View at Scopus
  54. S. Shelkovnikov, S. M. Summers, R. Elahimehr, G. Adams, R. E. Purdy, and N. D. Vaziri, “Effect of exercise training on aortic tone in chronic renal insufficiency,” American Journal of Hypertension, vol. 21, no. 5, pp. 564–569, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. D. R. Seals, C. A. DeSouza, A. J. Donato, and H. Tanaka, “Habitual exercise and arterial aging,” Journal of Applied Physiology, vol. 105, no. 4, pp. 1323–1332, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. N. D. Vaziri, Z. Ni, F. Oveisi, K. Liang, and R. Pandian, “Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency,” Hypertension, vol. 39, no. 1, pp. 135–141, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. G. A. Kaysen and J. P. Eiserich, “The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction,” Journal of the American Society of Nephrology, vol. 15, no. 3, pp. 538–548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Goicoechea, S. Garcia de Vinuesa, U. Verdalles et al., “Effect of allopurinol in chronic kidney disease progression and cardiovascular risk,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 8, pp. 1388–1393, 2010. View at Publisher · View at Google Scholar
  59. J. Vśquez-Vivar, B. Kalyanaraman, and P. Martásek, “The role of tetrahydrobiopterin in superoxide generation from eNOS: enzymology and physiological implications,” Free Radical Research, vol. 37, no. 2, pp. 121–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  60. A. C. F. Gorren and B. Mayer, “Tetrahydrobiopterin in nitric oxide synthesis: a novel biological role for pteridines,” Current Drug Metabolism, vol. 3, no. 2, pp. 133–157, 2002. View at Google Scholar · View at Scopus
  61. E. Podjarny, G. Hasdan, J. Bernheim et al., “Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5/6 nephrectomized rats,” Nephrology Dialysis Transplantation, vol. 19, no. 9, pp. 2223–2227, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Yamamizu, K. Shinozaki, K. Ayajiki, M. Gemba, and T. Okamura, “Oral administration of both tetrahydrobiopterin and L-arginine prevents endothelial dysfunction in rats with chronic renal failure,” Journal of Cardiovascular Pharmacology, vol. 49, no. 3, pp. 131–139, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. A. A. Reyes, I. E. Karl, and S. Klahr, “Role of arginine in health and in renal disease,” American Journal of Physiology, vol. 267, no. 3, pp. F331–F346, 1994. View at Google Scholar · View at Scopus
  64. H. Moradi, V. Kwok, and N. D. Vaziri, “Effect of chronic renal failure on arginase and argininosuccinate synthetase expression,” American Journal of Nephrology, vol. 26, no. 3, pp. 310–318, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Xiao, L. Wagner, J. Mahaney, and C. Baylis, “Uremic levels of urea inhibit L-arginine transport in cultured endothelial cells,” American Journal of Physiology, vol. 280, no. 6, pp. F989–F995, 2001. View at Google Scholar · View at Scopus
  66. L. Wagner, J. D. Klein, J. M. Sands, and C. Baylis, “Urea transporters are distributed in endothelial cells and mediate inhibition of L-arginine transport,” American Journal of Physiology, vol. 283, no. 3, pp. F578–F582, 2002. View at Google Scholar · View at Scopus
  67. T. A. Hardy and J. M. May, “Coordinate regulation of L-arginine uptake and nitric oxide synthase activity in cultured endothelial cells,” Free Radical Biology and Medicine, vol. 32, no. 2, pp. 122–131, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. S. M. Bode-Böger, J. Muke, A. Surdacki, G. Brabant, R. H. Böger, and J. C. Frölich, “Oral L-arginine improves endothelial function in healthy individuals older than 70 years,” Vascular Medicine, vol. 8, no. 2, pp. 77–81, 2003. View at Publisher · View at Google Scholar · View at Scopus
  69. J. P. Cooke, N. A. Andon, X. J. Girerd, A. T. Hirsch, and M. A. Creager, “Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta,” Circulation, vol. 83, no. 3, pp. 1057–1062, 1991. View at Google Scholar · View at Scopus
  70. P. Clarkson, M. R. Adams, A. J. Powe et al., “Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults,” Journal of Clinical Investigation, vol. 97, no. 8, pp. 1989–1994, 1996. View at Google Scholar · View at Scopus
  71. R. H. Böger, “Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor,” Journal of Nutrition, vol. 134, no. 10, pp. 2842S–2847S, 2004. View at Google Scholar · View at Scopus
  72. L. Jin, R. B. Caldwell, T. Li-Masters, and R. W. Caldwell, “Homocysteine induces endothelial dysfunction via inhibition of arginine transport,” Journal of Physiology and Pharmacology, vol. 58, no. 2, pp. 191–206, 2007. View at Google Scholar · View at Scopus
  73. J. T. Kielstein and C. Zoccali, “Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?” American Journal of Kidney Diseases, vol. 46, no. 2, pp. 186–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. C. Baylis, “Arginine, arginine analogs and nitric oxide production in chronic kidney disease,” Nature Clinical Practice Nephrology, vol. 2, no. 4, pp. 209–220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada, “Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure,” The Lancet, vol. 339, no. 8793, pp. 572–575, 1992. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Fliser, F. Kronenberg, J. T. Kielstein et al., “Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2456–2461, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Ravani, G. Tripepi, F. Malberti, S. Testa, F. Mallamaci, and C. Zoccali, “Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach,” Journal of the American Society of Nephrology, vol. 16, no. 8, pp. 2449–2455, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. J. M. Young, N. Terrin, X. Wang et al., “Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 4, no. 6, pp. 1115–1120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Juonala, J. S. A. Viikari, G. Alfthan et al., “Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study,” Circulation, vol. 116, no. 12, pp. 1367–1373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  80. V. Achan, M. Broadhead, M. Malaki et al., “Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 8, pp. 1455–1459, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. J. T. Kielstein, R. H. Böger, S. M. Bode-Böger et al., “Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease,” Journal of the American Society of Nephrology, vol. 10, no. 3, pp. 594–600, 1999. View at Google Scholar · View at Scopus
  82. K. Matsuguma, S. Ueda, S. I. Yamagishi et al., “Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease,” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2176–2183, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. R. H. Böger, K. Sydow, J. Borlak et al., “LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases,” Circulation Research, vol. 87, no. 2, pp. 99–105, 2000. View at Google Scholar · View at Scopus
  84. R. Saran, J. E. Novak, A. Desai et al., “Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study,” Nephrology Dialysis Transplantation, vol. 18, no. 11, pp. 2415–2420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. H. Dayoub, V. Achan, S. Adimoolam et al., “Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence,” Circulation, vol. 108, no. 24, pp. 3042–3047, 2003. View at Publisher · View at Google Scholar · View at Scopus
  86. C. W. Lu, Z. Guo, M. Feng, Z. Z. Wu, Z. M. He, and Y. Xiong, “Ex vivo gene transferring of human dimethylarginine dimethylaminohydrolase-2 improved endothelial dysfunction in diabetic rat aortas and high glucose-treated endothelial cells,” Atherosclerosis, vol. 209, no. 1, pp. 66–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. B. Torondel, M. Nandi, P. Kelly, B. Wojciak-Stothard, I. Fleming, and J. Leiper, “Adenoviral-mediated overexpression of DDAH improves vascular tone regulation,” Vascular Medicine, vol. 15, no. 3, pp. 205–213, 2010. View at Publisher · View at Google Scholar · View at Scopus